Liraglutide, a GLP-1 agonist, may reduce post-prandial glucose excursions and HbA1c in T1D but also may increase hypoglycemia and ketosis [166,167], making it unlikely to gain widespread use in T1D management. This evidence concerns the gene GCG and Hypoglycemia.